Martin Shkreli, former CEO of Turing Pharmaceuticals AG, center, pauses as he speaks to members of the media with attorney Benjamin Brafman, right, outside federal court in the Brooklyn borough of New York, US, on Saturday, August 4, 2017.
Peter Foley Bloomberg Getty Images
The Federal Trade Commission on Friday asked the judge to hold the well-known “bro pharma” Martin Shkreli in contempt of court to form a new drug company in violation of the ban on convicted fraudsters from working in the pharmaceutical industry.
Shkreli, who was released from prison last year, has been banned “forever directly or indirectly
participate in the pharmaceutical industry in any way” as a result of the FTC’s antitrust lawsuit against him and the previous drug company he founded.
The FTC, in a Manhattan federal court filing, noted that Shkreli in July announced the formation of a new company, Druglike, “which appears to be involved in the pharmaceutical industry.”
The agency said those actions, as well as Shkreli’s failure to pay his nearly $25 million portion of the $64.6 million judgment owed in the lawsuit, indicate he violated a court order in the case.
This is new news. Please check back for updates.